Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 1,101–1,200 of 1,733
Cachexia in Clinical Practice: Experience from an Endocrine-Led Care ModelPreprint
Murthy, A., Simons, M., Jablonski, A., Hurd, M. A., Shukla, A. P., & Goncalves, M. D. (2025) · medRxiv · doi:10.1101/2025.07.09.25331020 · Cited by 1
Rahman, H. H., Stokey, W. R., & Munson‐McGee, S. H. (2025) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2025.104906 · Cited by 1
Gofur, M. R. (2021) · Journal of Bio-Science · doi:10.3329/jbs.v29i0.54833 · Cited by 1
“Low plasma testosterone is also observed in men with comorbidities like obesity, diabetes and obstructive sleep apnea (Bhasin et al. 2018), and such comorbidities are highly prevalent in COVID-19 patients, and thus consider as risk factors for COVID-19 (Mehra et al.”
BackgroundComplex metabolic–endocrine syndromes: associations with cardiovascular disease
Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00010-3 · Cited by 2
Brigante, G., Costantino, F., Bellelli, A., Boni, S., Furini, C., Cucchiara, R., & Simoni, M. (2025) · Andrology · doi:10.1111/andr.70104 · Cited by 1
Hohl, A., Ronsoni, M. F., & Lee, S. V. D. S. (2024) · Springer eBooks · doi:10.1007/978-3-031-65245-5_6 · Cited by 1
Acquired Male Hypogonadism in the Post-Genomic Era—A Narrative Review
Grande, G., Graziani, A., Toni, L. D., Garolla, A., Milardi, D., & Ferlin, A. (2023) · Life · doi:10.3390/life13091854 · Cited by 2
“In fact, current clinical guidelines on this topic acknowledge important gaps in the current evidence base that have led to important differences in interpretation and approaches for optimizing individualized management of patients, especially for older men with non-classical hypogonadism [1].”
BackgroundInfluentialDiagnosis and Treatment of Primary, Secondary, and Functional Male Hypogonadism: A Narrative Review
Mutlu, E., Aydemir, E. E., & Emral, R. (2025) · Ankara Üniversitesi Tıp Fakültesi Mecmuası · doi:10.65092/autfm.1762927 · Cited by 2
Glucose ingestion does not lower testosterone concentrations in men on testosterone therapy
Dhindsa, S., Ghanim, H., McPhaul, M. J., Ghoshal, A. K., & Dandona, P. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241252510 · Cited by 1
Bonenti, B., Puljević, C., Ferris, J., Barratt, M. J., O’Connor, T., & Piatkowski, T. M. (2025) · Journal of Drug Issues · doi:10.1177/00220426251403911 · Cited by 1
Delayed Diagnosis of Klinefelter Syndrome: A Case Report
Sargsyan, A. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105948 · Cited by 1
Molecular and Biological Factors in Aging
Litke, R. R., & Mobbs, C. V. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_102 · Cited by 1
Osteoporoza pri moških – pomen hipogonadizma
Antonič, K. G., & Kocjan, T. (2023) · Slovenian Medical Journal · doi:10.6016/zdravvestn.3435
“…na spodnji meji normale, določimo vezalno beljakovino za spolne hormone ( an-gl. sex hormone binding globulin, SHBG) in albumin, ter izračunamo prosti in biorazpoložjivi testosteron v serumu, ki odražata raven bioaktivnega testosterona bolj natančno kakor meritev celokupnega testosterona (12).”
BackgroundTremelimumab for the treatment of hepatocellular carcinoma
Sogbe, M., Sangro, P., de la Torre‐Aláez, M., & Sangro, B. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2550711 · Cited by 1
“Per U.S. prescribing guidance, patients weighing less than 30 kg require a dose reduction of tremelimumab to 4 mg/kg; however, the European Summary of Product Characteristics (SmPC) specifies a threshold of <40 kg for this adjustment [26].”
Al-Qazzaz, H. K., & Al-Awadi, S. J. A. (2022) · AIP conference proceedings · doi:10.1063/5.0094496 · Cited by 1
62-Year-Old Man With Abdominal Pain
Dunn, R., & Sahni, N. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.06.033 · Cited by 1
Association of age and insulin resistance with sex hormone-binding globulin levels in healthy men
Porgere, I. F., Rocha, B. M., Escott, G. M., Silva, L. C. F., Freitas, P. A. C., Satler, F., & Silveiro, S. P. (2025) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0360 · Cited by 1
The Application of Heavy Strength Training in Relative Energy Deficiency in Sport
Hooper, D. R. (2019) · Journal of Science in Sport and Exercise · doi:10.1007/s42978-019-00043-3 · Cited by 1
Misadventures in Toxicology: Concentration Matters for Testosterone-Induced Neurotoxicity
Willson, C. (2023) · Toxics · doi:10.3390/toxics11030258 · Cited by 1
“, testosterone that is unbound and bound by sex hormone binding globulin (SHBG) and albumin), while “free testosterone” or testosterone that is not bound to SHBG and albumin constitutes only 2–4% of total circulating testosterone; 50–60% of total testosterone is bound by SHBG and is generally not considered available…”
BackgroundAlger, M., Luera, N. A., & Weiner, R. (2021) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001307 · Cited by 1
Testosterone and Bone Health in Men
Kafel, H., & Basaria, S. S. (2026) · Current Osteoporosis Reports · doi:10.1007/s11914-026-00971-4 · Cited by 2
Male hypogonadism and pre-diabetes interplay: association or causal interaction? A systematic review
Greco, C., Corleto, R., Ebert, R., Simoni, M., Rochira, V., & Santi, D. (2021) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2021.14 · Cited by 1
Male Hypogonadism and Infertility
Turner, H. (2025) · Journal of Medical Clinical Case Reports · doi:10.47485/2767-5416.1123 · Cited by 1
ERKRANKUNGEN DER ENDOKRINEN ORGANE UND DES STOFFWECHSELS
Jung, N., Mayet, W.-J., Mertens, P. R., Meyer, J. S., Müller, O.-A., Pfeifer, M., Schellinger, P. D., Weiss, N., & Wendtner, C.-M. (2020) · Elsevier eBooks · doi:10.1016/b978-3-437-06282-7.50015-2 · Cited by 1
Lee, J., & Park, H.-J. (2026) · American Journal of Men s Health · doi:10.1177/15579883251412966 · Cited by 1
“…bone strength, less hair, and skin changes), mood (e.g., depression, decreased concentration and cognitive function, and increased fatigue), and sexual changes (e.g., diminished libido, erectile dysfunction, and reduced sexual drive) (Bhasin et al., 2018; Indirli et al., 2023; Lim & Park, 2025).”
Androgen Deficiency In Men With Chronic Obstructive Pulmonary Disease
Podzolkov, V. I., Ishina, T. I., & Medvedev, I. D. (2022) · Russian Open Medical Journal · doi:10.15275/rusomj.2022.0110 · Cited by 1
“hand, the limitation of TRT use may be associated with the development of side effects, such as erythrocytosis, sleep apnea, and stimulation of prostate cancer growth [13].”
BackgroundInfluentialWeber, M. A., Aslam, S., Efros, M. D., Chan, A., Khan, N., Li, X., Dubcenco, E., & Miller, M. G. (2024) · Andrology · doi:10.1111/andr.13779 · Cited by 2
Волкова, Н. И., Сафроненко, А. В., Ганцгорн, Е. В., & Degtyareva, Y. S. (2022) · Obesity and metabolism · doi:10.14341/omet12850 · Cited by 2
Murakami, R., Ohsaki, Y., Ito, H., Ho, H., Agista, A. Z., Chiang, Y., Chen, Y.-L., Maekawa, M., Hirose, T., Hara, K., et al. (2026) · Foods · doi:10.3390/foods15061070 · Cited by 4
“Ts replacement therapy (TRT) is available to treat LOH [11]; however, TRT has been reported to have adverse effects that may worsen prostate disease, exacerbate sleep apnea, and impair spermatogenic function, thus limiting its clinical use [12,13].”
Niu, L., Du, Z., Xie, Z., Liu, X., Wang, Q., Zhao, Y., Wang, H., Hao, C., Xue, D., & Wang, L. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.085 · Cited by 2
Testosteronsubstitution im Alter — das Für und Wider
Schmidt, R., & Palitzsch, K. (2019) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-019-0965-y · Cited by 1
Initiating male contraception methods
Wu, F. C. W., & Lo, K. C. (2024) · Andrology · doi:10.1111/andr.13694 · Cited by 1
Self-citationHipercalciuria significativa con desenlace inesperado
Tovar, A. P., Cali, M. O., Jiménez-Salazar, S., Mendez, H., & Buitrago-Toro, K. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.2.771 · Cited by 1
Proteomics for the identification of peripheral markers in pituitary disease
Grande, G., GRAZIANI, A., Toni, L. D., et al. (2024) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04075-7 · Cited by 1
Male hypogonadism in patients on maintenance hemodiafiltration: prevalence and therapeutic effect
Carvalho, M. S., Torres, R. C., Toniasso, I. M., Magalhäes, A. O., Borges, C. M., Rocha, É. P. D. [., Kojima, C. A., & Elias, R. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1744953 · Cited by 1
Castro, H. M., Knoblovits, P., Furcada, J. M., Vito, E. L. D., Suarez, S. M., & Costanzo, P. (2024) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2024.09.006 · Cited by 1
Testosterone Use in the Perioperative Setting
Goyette, B. N., Hudnall, M. T., & Halpern, J. A. (2022) · Current Sexual Health Reports · doi:10.1007/s11930-021-00322-7 · Cited by 1
Raheem, O. A., & Barham, A. (2024) · Urology · doi:10.1016/j.urology.2024.11.005 · Cited by 1
Rodrigues, M. I., Zanoni, R. D., dos Santos, A. A., Cavalcante, A. P. D. S. A., Neto, A. A. C., Antunes, G., Ribeiro, L. S. C., de Sousa, J. O., Almeida, J. V. D. R., Castro, J. L., et al. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n2-105 · Cited by 1
Yeap, B. B., Wittert, G., Wu, F. C. W., Vanderschueren, D., & ORWOLL, E. S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00440 · Cited by 1
Self-citationRyu, C. H., Park, S., Yeo, J. K., & Park, M. G. (2022) · Journal of Men s Health · doi:10.31083/j.jomh1804099 · Cited by 1
“TRT is generally contraindicated for patients with prostate cancer because of the risk of activation and growth of prostate cancer cells caused by TRT [2,3].”
BackgroundJohannsen, E. B., Ridder, L. O. R., Schou, A. N., Wang, J., Farup, J., Lin, L., Just, J., & Gravholt, C. H. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag240 · Cited by 1
Charfadine, Y. Y., Koularambaye, R., Béboy, S. N. E., Fifen, R. N., Jignoua, Y. S., Dzeufiet, P. D. D., & Moundipa, P. F. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i7.6683 · Cited by 1
“Conventional medicinal treatments, such as testosterone supplementation 5 , have been shown to be effective but, are limited due to undesirable side effects and constraints such as disruption of treatment and high cost 6 .”
BackgroundDerkach, K. V., Morina, I. Y., Bayunova, L. V., et al. (2023) · Obesity and metabolism · doi:10.14341/omet13018 · Cited by 1
“…используют заместительную терапию препаратами тестостерона, и это не только нормализует андрогенный статус, но также сни-жает массу тела, повышает чувствительность тканей-ми-шеней, включая компоненты ГГТ, к инсулину и лептину, и в ряде случаев приводит к улучшению сперматогенной функции [3, 4].”
Wu, S., Hilton, O., Pereira, B. I., Girometti, N., Milinkovic, A., Ollandini, G., & Boffito, M. (2022) · International Journal of STD & AIDS · doi:10.1177/09564624221083760 · Cited by 2
“Since SHBG levels are commonly increased in PLWH,(8,9) current guidelines recommend assessing free testosterone (FT) in individuals with suspected clinical hypogonadism to improve diagnostic accuracy.(10) The gold standard for FT measurement is by equilibrium dialysis, however this may be costly and not routinely avai…”
BackgroundErwiderung auf den Leserbrief zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“
Jaschke, N., Rachner, T. D., & Hofbauer, L. C. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1423-2691 · Cited by 1
Zhang, X., Zhang, Q., Wang, M.-J., Sun, Y., & Lu, J.-G. (2026) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v18.i1.114445 · Cited by 1
Schuppe, H., Köhn, F., & Linn, T. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-63400-4_156 · Cited by 1
Diagnosis and management of male hypogonadism in Germany
Zitzmann, M., Ortius‐Lechner, D., Thierfelder, N., Schindler, C. J. A., & Häckl, D. (2025) · The Aging Male · doi:10.1080/13685538.2025.2602243 · Cited by 1
Parental Psychological Control and Aggression: A Systematic Review and Meta-analysis
Liu, J., Gu, Y., & Zhang, Y. (2026) · Current Psychology · doi:10.1007/s12144-026-09130-5 · Cited by 1
“Therefore, under parental psychological control, males are more likely to use externalized aggressive behavior to cope with psychological threats (Bhasin et al., 2018).”
Nosologie andrologischer Krankheitsbilder
Nieschlag, E., Tüttelmann, F., Kliesch, S., & Behre, H. M. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-61904-9_4-1 · Cited by 1
Negri, F., Boeri, L., Pozzi, E., Raffo, M., Ramadani, R., Birolini, G., Passarelli, F., Corsini, C., Belladelli, F., Bertini, A., et al. (2025) · Andrology · doi:10.1111/andr.70054 · Cited by 1
Testosteronsubstitution und etwaige Nebenwirkungen
Zitzmann, M., Michel, M. C., & Sperling, H. V. (2024) · Die Urologie · doi:10.1007/s00120-024-02455-8 · Cited by 1
Practice guideline for pharmacists: The management of late-onset hypogonadism
Matai, A., Abdullahi, M., Beahm, N. P., & Sadowski, C. A. (2021) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635211047468 · Cited by 2
“This should be treated with conventional medications (hCG or TT).(2,7) Functional hypogonadism is the absence of alterations to the HPG axis and is caused by conditions suppressing gonadotropin and testosterone levels.”
BackgroundInfluentialMason, M. M., Nackeeran, S., Lokeshwar, S. D., Blachman-Braun, R., & Ramasamy, R. (2022) · Urology · doi:10.1016/j.urology.2022.02.010 · Cited by 1
Stress-associated testosterone suppression: central adaptation or hypogonadism?
Friedl, K. E., Nindl, B. C., & Potter, A. W. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag181 · Cited by 4
Vargas‐Ortega, G., Pérez-Villarreal, G., de Santiago, A. R., Balcázar‐Hernández, L., Mendoza‐Zubieta, V., Landa-Gutierrez, O., Estrada-Robles, C., & González‐Virla, B. (2019) · International Journal of Endocrinology · doi:10.1155/2019/2356580 · Cited by 2
“T, has been associated with a positive effect on cardiovascular disease, low urinary tract symptoms (LUTS), and erectile function [1, 2].”
BackgroundInfluentialKisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders
Pierret, A. C. S., Patel, A., Daniels, E., Comninos, A. N., Dhillo, W. S., & Abbara, A. (2025) · Andrology · doi:10.1111/andr.13843 · Cited by 3
López, G. P., Cebrián, S. B., Fernández, L. G., & Albarrán, O. G. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.09.003 · Cited by 2
Male ductal carcinoma in situ: diagnosis and management of a rare disease in men
Tian, C., Alvarado, R., Kim, T., et al. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-256608 · Cited by 1
Luo, M., Xia, W., Jiang, L., Cai, Y., Lan, Z., & Xiao, Z. (2026) · Neurosurgical Review · doi:10.1007/s10143-025-04028-5 · Cited by 1
“Testosterone, the predominant androgen in males, has been shown in multiple studies to support higher bone mineral density and greater bone strength through mechanisms such as promoting osteoblast proliferation, inhibiting osteoclast activity, and enhancing osteocalcin secretion [53 ].”
Cancer immunotherapy associated hypophysitis: Pathophysiology and management
Das, S. K., & Sen, K. (2022) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2022.15.2.0819 · Cited by 1
“300 whereas in reproductive women reduced level of estradiol is observed; in case of post reproductive aged women subnormal level of FSH and LH indicating development of hypogonadotropic hypogonadism [2,26].”
BackgroundBuriti (Mauritia Flexuosa) Pulp and Oil as an Adjuvant in Testosterone Replacement Therapy
Silva, R. P. M. (2018) · Global Journal of Endocrinological Metabolism · doi:10.31031/gjem.2018.02.000535 · Cited by 1
“There are some potential undesirable and adverse effects related to TRT: worsening of apnea [16]; reduction of HDL-cholesterol levels [17]; erythrocytosis, particularly with testosterone ester injections [17,18]; venous thromboembolism as a consequence of erythrocytosis because the risk of venous thromboembolic diseas…”
BackgroundThe Complex Relationship Between Erectile Dysfunction and Hypogonadism in Diabetes Mellitus
Holland, L. C., Beilan, J. A., Tatem, A. J., & Lipshultz, L. I. (2019) · Current Sexual Health Reports · doi:10.1007/s11930-019-00216-9 · Cited by 1
Poopuangpairoj, T., Sirisopana, K., Ketsuwan, C., Kongchareonsombat, W., Phengsalae, Y., Matang, W., & Sangkum, P. (2024) · Research and Reports in Urology · doi:10.2147/rru.s476804 · Cited by 2
“14,17 Furthermore, the data are limited, especially in Asian populations.”
BackgroundSee, C. K., Turnbull, D. A., Ritson, F., Martin, S., Tully, P. J., & Wittert, G. (2019) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2017-004035 · Cited by 2
Pagadala, M. S., Teerlink, C. C., Jasuja, G. K., Palnati, M., Anglin-Foote, T. R., Chang, N.-C. N., Deka, R., Lee, K. M., Agiri, F. Y., Amariuta, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57372-x · Cited by 2
Unsafe Behaviors and Anabolic Steroid Use: Implications for Public Health
Ip, E. J., & Silva, M. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_134 · Cited by 1
Testosterone Treatment in Male Patients with Klinefelter’s Syndrome
Corona, G., Guaraldi, F., Dicuio, M., Sforza, A., Krausz, C. G., & Maggi, M. (2020) · Trends in andrology and sexual medicine · doi:10.1007/978-3-030-51410-5_26 · Cited by 2
Hendawy, L. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/npsh6 · Cited by 1
Success in Harmonization of Laboratory Measurements, Yet More to Be Done
Vesper, H. W., Sugahara, O., Pokuah, F., Danilenko, U., & Lyle, A. N. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfac061 · Cited by 2
Molecular and Biological Factors in Aging
Litke, R. R., & Mobbs, C. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_102-1 · Cited by 1
Predictive Factors of Efficacy Maintenance after Testosterone Treatment Cessation
Park, M. G., Yeo, J. K., Park, S., Na, W., & Moon, D. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020151 · Cited by 2
“In terms of prostate safety, the relative contraindications [23,24] for patients with severe lower urinary tract symptoms (LUTS) that were listed in previous guidelines have been excluded from the current guidelines [1,20,21,25,26], as subsequent studies suggested that TRT is helpful for patients with LUTS.”
BackgroundHypogonadism in Men With Hepatitis C: What Is a Clinician to Do?
Brown, T. T. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy968 · Cited by 2
Testosteronmangel im Alter – was ist zu tun?
Jaschke, N., Rachner, T. D., & Hofbauer, L. C. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1240-9784 · Cited by 1
“Nur falls beide Kriterien erfüllt sind, kann von einem Hypogonadismus gesprochen werden [7].”
BackgroundHormone Therapy for Transgender and Gender-Diverse Patients
Grock, S., Patel, R., & Ahern, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-69997-9_4 · Cited by 1
Male hypogonadism with its systemic complications
Niedobylski, S., Laszczak, K., Warchoł, K., Marczak, A., Dobosz, M., Lewicki, M., & Obel, E. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.09.020 · Cited by 1
What to Measure: Testosterone or Free Testosterone?
Wang, C., & Swerdloff, R. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-77111-9_1 · Cited by 2
Self-citationStraseski, J. A., Vesper, H. W., Long, T. A., & Horowitz, G. L. (2026) · Clinical Chemistry · doi:10.1093/clinchem/hvag068
Testosterone and congestive heart failure
Enina, T. N., Va, K., & Soldatova, A. M. (2022) · Kardiologiia · doi:10.18087/cardio.2022.7.n1242 · Cited by 3
Ashley, K. B., Arroyo, H., Casasnovas, C. E., Kertzner, R. M., Lichtenstein, M., & Lyon, M. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-80665-1_15 · Cited by 2
Zafrani, Z., Khan, S. S., & Zitzmann, M. (2026) · Cells · doi:10.3390/cells15151319 · Cited by 3
“In men with obesity or diabetes and associated hypogonadism, particularly those wishing to preserve fertility, GLP-1-based therapies may represent a first-line or adjunctive strategy, with TRT reserved for persistent symptoms or refractory biochemical deficiency [3,12].”
InfluentialWhite, W. B., Bernstein, J. S., Morgentaler, A., & Dhingra, O. (2022) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2022.0011 · Cited by 1
Carswell, J. M., Barrera, E. P., Liu, E., & Roberts, S. A. (2024) · Transgender Health · doi:10.1089/trgh.2022.0215 · Cited by 1
“16 This study aimed to explore the use of serum free testosterone concentrations in transmasculine patients as a more reliable indicator of monitoring gender-af fi rming testosterone therapy than total testosterone concentration.”
Clinical significance of sex hormones in COVID-19
Mikhail, N. E., & Wali, S. (2020) · Frontiers in Women’s Health · doi:10.15761/fwh.1000183 · Cited by 1
Swee, D. S., & Quinton, R. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001689 · Cited by 1
“For instance, the use of synthetic androgens rather than native testosterone in the treatment of hypogonadal men is specifically discouraged(2) and testosterone treatment is adjusted so as to achieve mid-range serum levels.(3) Similar standards apply to the estrogen replacement of transgender women.”
BackgroundVaricocele and low testosterone
Steele, G. L., & Tanrikut, C. (2026) · Fertility and Sterility · doi:10.1016/j.fertnstert.2026.03.011 · Cited by 2
Principles of Diagnosis and Treatment of Osteoporosis
Caraccio, D. M., & Jones, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-42894-5_7 · Cited by 2
Wang, M., Tapper, E. B., Lai, J. C., & Mauro, E. (2025) · Liver International · doi:10.1111/liv.70443 · Cited by 1
Yuan, X., Xiong, X., & Xue, J. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12628 · Cited by 4
Chandra, M. S., Wang, C., Gagliano‐Jucá, T., Gaikwad, E., Shang, Y. V., Pencina, K. M., & Bhasin, S. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.019 · Cited by 1
Self-citationIs Testosterone the “Fountain of Youth” for Aging Men?
Giagulli, V. A., Lisco, G., Mariano, F., Tullio, A. D., & Triggiani, V. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220516160435 · Cited by 1
Every Third Male Patient with Acromegaly Recovers from Hypogonadism after Neurosurgical Treatment
Derwich-Rudowicz, A., Nijakowski, K., Biczysko, A., Ziemnicka, K., Liebert, W., Ruchała, M., & Sawicka‐Gutaj, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185526 · Cited by 1
Leinonen, J. T., Mars, N., Lehtonen, L. E., Ahola‐Olli, A., Ruotsalainen, S., Lehtimäki, T. J., Kähönen, M. A. P., Raitakari, O. T., FinnGen, Daly, M. J., et al. (2021) · medRxiv · doi:10.1101/2021.04.23.21255981 · Cited by 1
“Yet, these studies have yielded partly mixed results, and, in many instances, the proposed 35 relationships between T, complex traits and disease remain elusive (2, 7-11).”
BackgroundResultThe effect of stress on testosterone and sexual function
McGonagle, E., Thomas, J., Marrufo, I. M., & Khera, M. (2026) · International Journal of Impotence Research · doi:10.1038/s41443-026-01279-8 · Cited by 1
Fattahi, S., Chen, M., Wu, J., Smart, A., & D'Amico, A. V. (2025) · Cancer Medicine · doi:10.1002/cam4.71124 · Cited by 1
“A low testosterone level was defined as a serum level 264 ng/dL based on the Endocrine Society Clinical Practice Guideline [24] with a 20% margin to account for the daily and seasonal variations in serum testosterone levels [25, 26].”
Pilz, S., Vila, G., Kiefer, F. W., Luger, A., Krebs, M., Scherer, T., Baumgartner-Parzer, S. M., Riedl, S., Stepan, V., Buchinger, W., et al. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00292-4 · Cited by 1
Schmidt, M. K., Rohayem, J., Zitzmann, M., Gelhorn, H. L., & Schneider, G. (2022) · Andrologia · doi:10.1111/and.14370 · Cited by 1
“It is characterized by symptoms of androgen deficiency in combination with low- serum concentration of testosterone in males of all ages (Bhasin et al.2018; Corona et al., 2020; Dohle et al., 2018).”
BackgroundCraniopharyngioma and Eating Disorders
Bondanelli, M., Manzato, E., Gagliardi, I., & Ambrosio, M. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-81174-7_21 · Cited by 1
Prevalance and Risk Factors of Hypogonadism in Male Patients with Type 2 Diabetes in El Minya, Egypt
(2023) · doi:10.31038/edmj.2023711
“Recently, studies have shown that hypogonadism is closely related to the development of diabetes [9].”
Background
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.